UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities and Exchange Act of 1934

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 26, 2021

BIOSECURITY TECHNOLOGY, INC.

(Exact Name of Registrant as Specified in its Charter)

Nevada		333-224157		35-2606208
(State of Other Jurisdiction)		(Commission File Number)		(IRS Employer Identification Number)

3821 S 148th Street, Omaha, Nebraska 68144

(Address of principal executive offices, including zip code)

800-494-9604

(Registrant’s telephone number, including area code)

Copies to:

Peter Campitiello, Esq.

McCarter & English, LLP

Two Tower Center Boulevard

East Brunswick, New Jersey 08816

Tel: 732-867-9741

Fax: 732-392-1901

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Merger Act (17 CFR 240.14a -12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Merger Act (17 CFR 240.14d -2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Merger Act (17 CFR 240.13e -4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which

registered

Common Stock, $0.0001 par value per share

BSEC

OTC Markets

ITEM 4.01.

CHANGES IN REGISTRANT’S CERTIFYING ACCOUNTANT.

(a)

Dismissal of Independent Registered Public Accounting Firm

Effective July 26, 2021, PLS, CPA (“PLS”) was dismissed as the independent registered public accounting firm of Biosecurity Technology Inc. (the “Company”). The Company’s Board of Directors, acting as its audit committee, approved the dismissal of PLS.

PLS’s reports on the Company’s financial statements for the year ended June 30, 2020, did not contain any adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting principles.

During the year ended June 30, 2020 and through July 26, 2021, there were no disagreements with PLS on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of PLS, would have caused it to make reference thereto in connection with its reports on the financial statements for such years. During the year ended June 30, 2019, and through July 26, 2021, there were no matters that were either the subject of a disagreement as defined in Item 304(a)(1)(iv) of Regulation S-K or a reportable event as described in Item 304(a)(1)(v) of Regulation S-K.

The Company provided PLS with a copy of the foregoing disclosures and requested PLS to furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether or not PLS agrees with the disclosures. A copy of PLS’s letter is filed as Exhibit 16.1 to this Current Report on Form 8-K.

(b)

New Independent Registered Public Accounting Firm

On July 27, 2021, the Company’s Board of Directors, acting in the capacity of an audit committee, engaged Haynie & Company (“Haynie”) as the Company’s new independent registered public accounting firm to act as the principal accountant to audit the Company’s financial statements. During the Company’s fiscal years ended June 30, 2020 and 2019, and through July 27, 2021, neither the Company, nor anyone acting on its behalf, consulted with Haynie regarding the application of accounting principles to a specific completed or proposed transaction or the type of audit opinion that might be rendered on the Company’s financial statements, and no written report or oral advice was provided that Haynie concluded was an important factor considered by the Company in reaching a decision as to any such accounting, auditing or financial reporting issue.

Item 9.01.

Financial Statements and Exhibits.

Exhibit

No.

Description

16.1

Letter to the Securities and Exchange Commission from PLS, CPA regarding the matters disclosed in Item 4.01 of this Current Report on Form 8-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: July 29, 2021	BIOSECURITY TECHNOLOGY, INC.

	By:	/s/ Dan Lynn
		Name:	Dan Lynn
		Title:	Chief Executive Officer

BIOSECURITY TECHNOLOGY, INC. 8-K